Trials / Unknown
UnknownNCT04320303
CMV Infection and Immune Intervention After Transplantation
CMV Infection and Immune Intervention After Haploidentical Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of allo-HSCT. Its high incidence and poor prognosis can cause a series of terminal organ diseases such as CMV pneumonia, encephalitis, and enteritis,which seriously affecting the prognosis of patients post allo-HSCT. Our data show that rapid reconstruction of NK cells after transplantation can reduce the incidence of CMV infection. Patients with a rapid reconstruction of NKG2C after transplantation have a low CMV infection rate, and patients with strong secretion of IFN-gamma of NK after transplantation have low CMV infection. Our previous research showed that trophoblast cells transfected with IL-21 and 4-1BBL can achieve a large number of clinical-grade expansion of NK cells (mIL-21 / 4-1BBL NK cells), and mIL-21 / 4-1BBL NK cells It is safe to treat patients with minimal residual disease (MRD) positive AML after transplantation, and can induce MRD to turn negative. Previous studies have shown that adoptive infusion of expanded NK cells after haplotype transplantation is safe and can improve the functional reconstruction of NK cells. Therefore, we hypothesized that the infusion of NK cells can improve the antiviral capacity of NK cells, thereby effectively reducing the CMV infection. Incidence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | expanded NK cells | Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation. |
Timeline
- Start date
- 2020-03-23
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2020-03-24
- Last updated
- 2021-06-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04320303. Inclusion in this directory is not an endorsement.